Farxiga is one of the newest categories of antidiabetic medications, the SGLT2 (type 2 sodium-glucose co-transporter) inhibitors. It is co-marketed and manufactured in the U.S. by AstraZeneca and Bristol-Myers Squibb. Our experienced dangerous drug attorneys are currently reviewing potential claims for individuals who have suffered injuries due to taking Farxiga.
Farxiga was initially rejected by the FDA in 2012, due to concerns about its effect on the liver. In January of 2014, after additional research, the FDA approved the medication as the third of its type even though the agency had already begun receiving serious adverse event – diabetic ketoacidosis reports related to the group.
Potential injuries caused by Farxiga for the treatment of Type II diabetes may result in the need for expensive medical treatments, long term care, and irreversible harm. Thousands of patients who have suffered serious adverse events because of antidiabetic medication have filed lawsuits against the manufacturers of these new agents.